Effect of pharmaceutical follow-up in patients with secondary hyperparathyroidism treated with cinacalcet;Efecto del seguimiento farmacoterapéutico en pacientes con hiperparatiroidismo secundario tratados con cinacalcet

Farmacia Hospitalaria

Volumn 36, Issue 5, 2012, Pages 321-327

  Chemello, C ^a,b   Aguilera, M ^b   Calleja Hernandez M A ^b   Faus, M J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cinacalcet; Drug related problems; Pharmaceutical care; Pharmaceutical services; Pharmacotherapeutic follow up; Secondary hyperparathyroidism

Indexed keywords

CINACALCET; PARATHYROID HORMONE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; FOLLOW UP; HUMAN; HYPERPARATHYROIDISM; INTERVIEW; OUTCOME ASSESSMENT; PHARMACIST; PRACTICE GUIDELINE; QUASI EXPERIMENTAL STUDY; QUESTIONNAIRE;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PATIENT COMPLIANCE; PHARMACISTS; TREATMENT OUTCOME;

EID: 84866396351     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2011.03.008     Document Type: Article

References (30)

1. G.A. Block, K.J. Martin, A.L. de Francisco, S.A. Turner, M.M. Avram, and M.G. Suranyi Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525
2. th ed. 2005 McGraw-Hill
3. T. Apostolou, K. Kollia, L. Damianou, H. Kaitsioti, V. Kotsiev, and S. Dracopoulos Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet Transplant Proc 38 2006 3514 3516
4. I. Shahapuni, M. Monge, R. Oprisiu, H. Mazouz, P.F. Westeel, and P. Morinière Drug insight: renal indications of calcimimetics Nat Clin Pract Nephrol 2 2006 316 325
5. Ficha técnica Cinacalcet [consultado Jun 2010]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/ human/000570/WC500028900.pdf.
6. P. Messa, F. Macário, M. Yaqoob, K. Bouman, J. Braun, and B. Von Albertini The OPTIMA study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism Clin J Am Soc Nephrol 3 2008 36 45
7. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [consultado Mar 2008]. Disponible en: http://www.kidney.org/ professionals/kdoqi/guidelines-bone/index.htm
8. S.M. Moe, G.M. Shertow, J.W. Coburn, L.D. Quarles, W.G. Goodman, and G.A. Block Achieving NKF-K/DOQI TM bone metabolism and disease treatment goals with Cinacalcet HCL Kidney Int 67 2005 760 771
9. R.Z. Harris, D. Padhi, T.C. Marbury, R.J. Noveck, M. Salfi, and J.T. Sullivan Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily Am J Kidney Dis 44 2004 1070 1076
10. J.M. El-Amm, M.D. Doshi, A. Singh, S. Migdal, K. Morawski, and D. Sternbauer Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation Transplantation 83 2007 546 549
11. C.D. Hepler, and L.M. Strand Oportunities and responsabilities in the pharmaceutical care Am J Hosp Pharm 47 1990 533 543
12. Consensus Committee Third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM) Ars Pharmaceutical 48 2007 5 17
13. J.M. McKenney, and W.L. Harrison Drug-related hospital admissions Am J Hosp Pharm 33 2006 792 795
14. M.I. Baena, M.J. Faus, P.C. Fajardo, F.M. Luque, F. Sierra, and J. Martinez-Olmos Medicine-related problems resulting in emergency department visits Eur J Clin Pharmacol 62 2006 387 393
15. Grabe DW. Drug-related problems in the end-stage renal disease population. Medscape Pharmacists. 2000 [consultado Mar 2009]. Disponible en: www.medscape.com/viewarticle/408570
16. Consenso sobre Atención Farmacéutica. Madrid: Ministerio de Sanidad y Consumo; 2002.
17. Ley 28/2009, de 30 de diciembre, de modificación de la Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios. Madrid, España. BOE núm. 315, de 31 de diciembre.
18. U.S. Pharmacist. Postgraduate Healthcare Education. The Role of the Pharmacist in the Identification and Management of Secondary Hyperparathyroidism [consultado Mar 2008]. Disponible en: http://www.uspharmacist.com/oldformat. asp?url=ce/105514/default.htm
19. Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada Dader Method to provide pharmacotherapy follow-up Ars Pharm 46 2005 309 337
20. D.E. Morisky, L.W. Green, and D.M. Levine Concurrent and predictive validity of a self-reported measure of medication adherence Med Care 24 1986 67 74
21. H. Knobel, J. Alonso, J.L. Casado, J. Collazos, J. González, and I. Ruiz Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEMMA study AIDS 16 2002 605 613
22. M.D. Murray, M.E. Ritchey, J. Wu, and W. Tu Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease Arch Intern Med 169 2009 757 763
23. D.P. de Lyra, N. Kheir, J.P. Abriata, C.E. da Rocha, C.B. Dos Santos, and I.R. Pelá Impact of Pharmaceutical Care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP) Brazil Ther Clin Risk Manag 3 2007 989 998
24. K.K. Viktil, H.S. Blix, T.A. Moger, and A. Reikvam Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRP) Pharmacoepidemiol Drug Saf 15 2006 667 674
25. G. Reach Can technology improve adherence to long-term therapies? J Diabetes Sci Technol 3 2009 492 499
26. J. Dunbar-Jacob, and M.K. Mortimer-Stephens Treatment adherence in chronic disease J Clin Epidemiol 54 Suppl 1 2001 S57 S60
27. A.L. Serra, R. Savoca, A.R. Huber, U. Hepp, A. Delsignore, and M. Hersberger Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients Nephrol Dial Transplant 22 2007 577 583
28. M.D. Arenas, F. Alvarez-Ude, M.T. Gil, A. Moledous, T. Malek, and C. Nuñez Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis Nephrol Dial Transplant 22 2007 1639 1644
29. P. Ureña, S.H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, and N. Ashman Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study Nephrol Dial Transplant 24 2009 2852 2859
30. Kidney Disease: Improving Global Outcomes (KDIGO), CKD-MBD., Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int 76 Suppl 113 2009 S1 S130